Search tips
Search criteria 


Logo of jmedgeneJournal of Medical GeneticsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Med Genet. 2005 August; 42(8): 648–655.
PMCID: PMC1736119

Alternative mechanisms associated with silencing of CDKN1C in Beckwith–Wiedemann syndrome


Background: Mutations in the imprinted gene CDKN1C account for approximately 10% of Beckwith–Wiedemann syndrome (BWS) cases. Fibroblasts from BWS patients with loss of methylation (LOM) at the imprinting control region (ICR) KvDMR1 have reduced CDKN1C expression. Another group of BWS patients with downregulated CDKN1C expression but with normal methylation at KvDMR1 has been identified.

Objective: To investigate the mechanism of CDKN1C silencing in BWS in these two classes of patients.

Methods: The CDKN1C promoter region was analysed for changes in DNA methylation using bisulphite sequencing, and for alterations in chromatin structure using the chromatin immunoprecipitation (ChIP) assay.

Results: There was only spurious CpG methylation of the CDKN1C promoter in fibroblast DNA from both normal individuals and patients with BWS, irrespective of the methylation status of KvDMR1. There was no detectable change in chromatin structure at the CDKN1C promoter in patients with LOM at KvDMR1. BWS patients with downregulated CDKN1C and normal methylation at KvDMR1 had depletion of dimethylated H3-K4 and enrichment of dimethylated H3-K9 and HP1γ at the CDKN1C promoter, suggesting that in these cases gene silencing is associated with repressive chromatin changes.

Conclusions: CDKN1C may be downregulated by multiple mechanisms including some that do not involve promoter methylation. In BWS patients with normal methylation at KvDMR1 and reduced expression of CDKN1C, repressive chromatin may play a role, but the absence of methylation and repressive chromatin structure at the CDKN1C promoter in BWS patients with LOM at KvDMR1 argues for a direct role of this epimutation in silencing CDKN1C.

Full Text

The Full Text of this article is available as a PDF (233K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Maher ER, Reik W. Beckwith-Wiedemann syndrome: imprinting in clusters revisited. J Clin Invest. 2000 Feb;105(3):247–252. [PMC free article] [PubMed]
  • Lee MH, Reynisdóttir I, Massagué J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995 Mar 15;9(6):639–649. [PubMed]
  • Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 1995 Mar 15;9(6):650–662. [PubMed]
  • Zhang P, Liégeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature. 1997 May 8;387(6629):151–158. [PubMed]
  • Yan Y, Frisén J, Lee MH, Massagué J, Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev. 1997 Apr 15;11(8):973–983. [PubMed]
  • Chung WY, Yuan L, Feng L, Hensle T, Tycko B. Chromosome 11p15.5 regional imprinting: comparative analysis of KIP2 and H19 in human tissues and Wilms' tumors. Hum Mol Genet. 1996 Aug;5(8):1101–1108. [PubMed]
  • Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, Niikawa N, Ohashi H, Fukushima Y, Iida K, et al. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet. 1996 Jun;5(6):783–788. [PubMed]
  • Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, et al. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome. Nat Genet. 1996 Oct;14(2):171–173. [PubMed]
  • O'Keefe D, Dao D, Zhao L, Sanderson R, Warburton D, Weiss L, Anyane-Yeboa K, Tycko B. Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors. Am J Hum Genet. 1997 Aug;61(2):295–303. [PubMed]
  • Lam WW, Hatada I, Ohishi S, Mukai T, Joyce JA, Cole TR, Donnai D, Reik W, Schofield PN, Maher ER. Analysis of germline CDKN1C (p57KIP2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet. 1999 Jul;36(7):518–523. [PMC free article] [PubMed]
  • Arney Katharine L. H19 and Igf2--enhancing the confusion? Trends Genet. 2003 Jan;19(1):17–23. [PubMed]
  • Horike S, Mitsuya K, Meguro M, Kotobuki N, Kashiwagi A, Notsu T, Schulz TC, Shirayoshi Y, Oshimura M. Targeted disruption of the human LIT1 locus defines a putative imprinting control element playing an essential role in Beckwith-Wiedemann syndrome. Hum Mol Genet. 2000 Sep 1;9(14):2075–2083. [PubMed]
  • Fitzpatrick Galina V, Soloway Paul D, Higgins Michael J. Regional loss of imprinting and growth deficiency in mice with a targeted deletion of KvDMR1. Nat Genet. 2002 Nov;32(3):426–431. [PubMed]
  • Lewis Annabelle, Mitsuya Kohzoh, Umlauf David, Smith Paul, Dean Wendy, Walter Joern, Higgins Michael, Feil Robert, Reik Wolf. Imprinting on distal chromosome 7 in the placenta involves repressive histone methylation independent of DNA methylation. Nat Genet. 2004 Dec;36(12):1291–1295. [PubMed]
  • Kanduri Chandrasekhar, Fitzpatrick Galina, Mukhopadhyay Rituparna, Kanduri Meena, Lobanenkov Victor, Higgins Michael, Ohlsson Rolf. A differentially methylated imprinting control region within the Kcnq1 locus harbors a methylation-sensitive chromatin insulator. J Biol Chem. 2002 May 17;277(20):18106–18110. [PubMed]
  • Mancini-DiNardo Debora, Steele Scott J S, Ingram Robert S, Tilghman Shirley M. A differentially methylated region within the gene Kcnq1 functions as an imprinted promoter and silencer. Hum Mol Genet. 2003 Feb 1;12(3):283–294. [PubMed]
  • Thakur Noopur, Kanduri Meena, Holmgren Claes, Mukhopadhyay Rituparna, Kanduri Chandrasekhar. Bidirectional silencing and DNA methylation-sensitive methylation-spreading properties of the Kcnq1 imprinting control region map to the same regions. J Biol Chem. 2003 Mar 14;278(11):9514–9519. [PubMed]
  • Du Minjie, Beatty Linda G, Zhou Wenjing, Lew Jocelyne, Schoenherr Christopher, Weksberg Rosanna, Sadowski Paul D. Insulator and silencer sequences in the imprinted region of human chromosome 11p15.5. Hum Mol Genet. 2003 Aug 1;12(15):1927–1939. [PubMed]
  • Lee MP, DeBaun MR, Mitsuya K, Galonek HL, Brandenburg S, Oshimura M, Feinberg AP. Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5203–5208. [PubMed]
  • Smilinich NJ, Day CD, Fitzpatrick GV, Caldwell GM, Lossie AC, Cooper PR, Smallwood AC, Joyce JA, Schofield PN, Reik W, et al. A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):8064–8069. [PubMed]
  • Engel JR, Smallwood A, Harper A, Higgins MJ, Oshimura M, Reik W, Schofield PN, Maher ER. Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. J Med Genet. 2000 Dec;37(12):921–926. [PMC free article] [PubMed]
  • Diaz-Meyer N, Day CD, Khatod K, Maher ER, Cooper W, Reik W, Junien C, Graham G, Algar E, Der Kaloustian VM, et al. Silencing of CDKN1C (p57KIP2) is associated with hypomethylation at KvDMR1 in Beckwith-Wiedemann syndrome. J Med Genet. 2003 Nov;40(11):797–801. [PMC free article] [PubMed]
  • Tokino T, Urano T, Furuhata T, Matsushima M, Miyatsu T, Sasaki S, Nakamura Y. Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet. 1996 May;97(5):625–631. [PubMed]
  • Bliek J, Maas SM, Ruijter JM, Hennekam RC, Alders M, Westerveld A, Mannens MM. Increased tumour risk for BWS patients correlates with aberrant H19 and not KCNQ1OT1 methylation: occurrence of KCNQ1OT1 hypomethylation in familial cases of BWS. Hum Mol Genet. 2001 Mar 1;10(5):467–476. [PubMed]
  • DeBaun Michael R, Niemitz Emily L, McNeil D Elizabeth, Brandenburg Sheri A, Lee Maxwell P, Feinberg Andrew P. Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. Am J Hum Genet. 2002 Mar;70(3):604–611. [PubMed]
  • Clark SJ, Harrison J, Paul CL, Frommer M. High sensitivity mapping of methylated cytosines. Nucleic Acids Res. 1994 Aug 11;22(15):2990–2997. [PMC free article] [PubMed]
  • Kikuchi Takefumi, Toyota Minoru, Itoh Fumio, Suzuki Hiromu, Obata Toshiro, Yamamoto Hiroyuki, Kakiuchi Hideki, Kusano Masanobu, Issa Jean-Pierre J, Tokino Takashi, et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene. 2002 Apr 18;21(17):2741–2749. [PubMed]
  • Li Yinghua, Nagai Hirokazu, Ohno Toshihito, Yuge Masaaki, Hatano Sonoko, Ito Etsuro, Mori Naoyoshi, Saito Hidehiko, Kinoshita Tomohiro. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood. 2002 Oct 1;100(7):2572–2577. [PubMed]
  • Shin JY, Kim HS, Park J, Park JB, Lee JY. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res. 2000 Jan 15;60(2):262–265. [PubMed]
  • Shen LanLan, Toyota Minoru, Kondo Yutaka, Obata Toshiro, Daniel Sophia, Pierce Sherry, Imai Kohzoh, Kantarjian Hagop M, Issa Jean-Pierre J, Garcia-Manero Guillermo. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood. 2003 May 15;101(10):4131–4136. [PubMed]
  • Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 1997 Jun 15;25(12):2532–2534. [PMC free article] [PubMed]
  • Gabriel JM, Higgins MJ, Gebuhr TC, Shows TB, Saitoh S, Nicholls RD. A model system to study genomic imprinting of human genes. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14857–14862. [PubMed]
  • Strahl BD, Ohba R, Cook RG, Allis CD. Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14967–14972. [PubMed]
  • Minc E, Courvalin JC, Buendia B. HP1gamma associates with euchromatin and heterochromatin in mammalian nuclei and chromosomes. Cytogenet Cell Genet. 2000;90(3-4):279–284. [PubMed]
  • Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature. 2001 Mar 1;410(6824):116–120. [PubMed]
  • Caspary T, Cleary MA, Perlman EJ, Zhang P, Elledge SJ, Tilghman SM. Oppositely imprinted genes p57(Kip2) and igf2 interact in a mouse model for Beckwith-Wiedemann syndrome. Genes Dev. 1999 Dec 1;13(23):3115–3124. [PubMed]
  • Reik W, Brown KW, Schneid H, Le Bouc Y, Bickmore W, Maher ER. Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain. Hum Mol Genet. 1995 Dec;4(12):2379–2385. [PubMed]
  • Takai D, Gonzales FA, Tsai YC, Thayer MJ, Jones PA. Large scale mapping of methylcytosines in CTCF-binding sites in the human H19 promoter and aberrant hypomethylation in human bladder cancer. Hum Mol Genet. 2001 Nov 1;10(23):2619–2626. [PubMed]
  • Thompson JS, Reese KJ, DeBaun MR, Perlman EJ, Feinberg AP. Reduced expression of the cyclin-dependent kinase inhibitor gene p57KIP2 in Wilms' tumor. Cancer Res. 1996 Dec 15;56(24):5723–5727. [PubMed]
  • Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, Bolondi L, Croce CM, Barbanti-Brodano G, Negrini M. Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5445–5449. [PubMed]
  • Soejima Hidenobu, Nakagawachi Tetsuji, Zhao Wei, Higashimoto Ken, Urano Takeshi, Matsukura Shiroh, Kitajima Yoshihiko, Takeuchi Makoto, Nakayama Masahiro, Oshimura Mitsuo, et al. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer. Oncogene. 2004 May 27;23(25):4380–4388. [PubMed]
  • Weksberg R, Nishikawa J, Caluseriu O, Fei YL, Shuman C, Wei C, Steele L, Cameron J, Smith A, Ambus I, et al. Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum Mol Genet. 2001 Dec 15;10(26):2989–3000. [PubMed]
  • Sleutels Frank, Zwart Ronald, Barlow Denise P. The non-coding Air RNA is required for silencing autosomal imprinted genes. Nature. 2002 Feb 14;415(6873):810–813. [PubMed]
  • Thakur Noopur, Tiwari Vijay Kumar, Thomassin Helene, Pandey Radha Raman, Kanduri Meena, Göndör Anita, Grange Thierry, Ohlsson Rolf, Kanduri Chandrasekhar. An antisense RNA regulates the bidirectional silencing property of the Kcnq1 imprinting control region. Mol Cell Biol. 2004 Sep;24(18):7855–7862. [PMC free article] [PubMed]
  • Grandjean V, Smith J, Schofield PN, Ferguson-Smith AC. Increased IGF-II protein affects p57kip2 expression in vivo and in vitro: implications for Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5279–5284. [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group